SC-ENVIVA-FOREST-FUND
The Enviva Forest Conservation Fund (the Fund) today announced the recipients of its 2022 grants. The projects funded this year will help conserve more than 3,000 acres and protect ecologically sensitive bottomland hardwood forests in the Virginia-North Carolina coastal plains.
Including those announced today, the Fund has awarded 29 projects totaling more than $3,100,000 in grants over the past seven years. An estimated 33,000 acres will be protected when these projects reach completion. The forests conserved as a part of the Fund help clean drinking water, purify the air, buffer structures from storms, and provide habitat for many species of wildlife, while at the same time, providing jobs and economic opportunity for rural families and private landowners.
“The fund is well on its way to achieving its initial goal to protect over 35,000 acres of sensitive bottomland hardwood forests across Virginia and South Carolina,” said Thomas Meth, President of Enviva. “With more than three years left in the program, the Fund is poised to partner with more and more diverse conservation groups as well as supersede our commitment to long-term investments in forest stewardship for generations to come.”
The 2022 Enviva Forest Conservation Fund grant recipients include:
The Tar River Land Conservancy: Tar River Land Conservancy aims to purchase the Bowers Tract, consisting of 244 forested acres and 60 acres of agricultural upland fields. Fifty-four percent (219 acres) of the property is situated within the 100-year-old floodplain of Swift Creek, a major tributary of the Tar River. Adjoining the property, Swift Creek provides a habitat for numerous rare, threatened, and endangered aquatic species, including the federally protected Carolina Madtom, Tar River Spiny Mussel, and Neuse River Waterdog.
Three Rivers Land Conservancy: Three Rivers Land Conservancy aims to acquire 440 acres of bottomland hardwood forest adjacent to the Little River and Uwharrie National Forest in Montgomery County, North Carolina. The Little River Buffer and Cliffs natural areas are located on the property. Federally endangered Northern Long Eared Bat and the threatened Oak Toad, Alewife, and Blue Back Herring are all present within this forest acreage.
The Virginia Outdoors Foundation: The Virginia Outdoors Foundation aims to acquire the Turner Tract which lies on the state scenic Nottoway River near Cary's Bridge. This tract contains 134 acres of bottomland hardwoods (111 acres of general hardwoods and 23 acres of Cypress-Tupelo) which will be designated as "old growth" as well as hundreds of acres of working forest. This land contributes to the protected corridor on the Nottoway River and its conservation will support the effort to protect this unique and fragile Virginia resource with a “National Wild and Scenic River” designation. The balance of the tract will remain in working forest and/or agricultural use.
The Conservation Fund: The Conservation Fund will protect 1,915 acres dominated by native bottomland hardwoods, forested wetlands, and loblolly pine along the Nottoway River in Sussex County, Virginia. This project will add to the corridor of protected land along the Nottoway River with 3.5 miles of frontage along the Nottoway where federally endangered Roanoke Logperch and Dwarf Wedge Mussel are found. The property also features 2.5 miles of frontage on Black Branch Swamp, where over 220 acres of forested wetlands and 400 acres of bottomland hardwoods reside. Sustainable forest management and restoration to native longleaf pine and pine savanna on the property will help create a habitat for endangered species such as the Red-Cockaded Woodpecker. Once transferred to the Virginia Department of Wildlife Resources, the property will be open for hunting, hiking, fishing, boating, and wildlife watching.
Ducks Unlimited: Ducks Unlimited aims to acquire a total of 292 acres in Bertie and Gates counties in North Carolina, under two separate tracts - the Crawford Tract and the Gasking Swamp Tract. The Crawford Tract is home to the Red-Cockaded Woodpecker and will expand the adjacent (on 3 sides) Chowan Swamp Game Land, which is located in one of the most important river basins for anadromous fishes in North Carolina. The Gasking Swamp Tract will expand the adjacent Bertie County Game Land, which helps protect portions of the Cashie River Swamps’ small creeks, floodplain wetlands, and Significant Natural Heritage Areas. These tracts provide important travel corridors for black bears along the Cashie River and are recognized as a “Global Important Bird Area.”
“The Endowment continues to support the efforts of the Enviva Forest Conservation Fund. These long-term investments promote conservation, biological diversity, and ecosystem sustainability in these areas of North Carolina and Virginia,” said Teal Edelen, Program Officer at the U.S. Endowment for Forestry and Communities. “These grants support sources of clean air and water, protect threatened wildlife and plant life, and provide great opportunities for recreation in these areas.”
About the Enviva Forest Conservation Fund
The Enviva Forest Conservation Fund is a $5 million, 10-year program established by Enviva in December 2015 to protect environmentally sensitive bottomland and wetland forests. Administered by the U.S. Endowment for Forestry and Communities, the Fund awards grants annually to nonprofit organizations and government agencies for conservation projects. Learn more at http://envivaforestfund.org.
About the U.S. Endowment for Forestry and Communities
The U.S. Endowment for Forestry and Communities is a not-for-profit public charity working collaboratively with partners in the public and private sectors to advance systemic, transformative, and sustainable change for the health and vitality of the nation’s working forests and forest-reliant communities. To learn more about the Endowment, please visit our website at www.usendowment.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220920006011/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
